1703778-92-0
Chemical Structure
MC-betaglucuronide-MMAE-1
- CAS No.: 1703778-92-0
- Formula:C66H98N8O20
- Molecular Weight:1323.53
IUPAC Name: (2S,3S,4S,5R,6S)-6-(4-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl)-2-(3-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)propanamido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
InChIKey: SBQIJGOPQUXPJF-CDCONWBCSA-N
SMILES: O[C@H]1[C@H](O)[C@@H](O)[C@H](OC2=C(NC(CCNC(CCCCCN3C(C=CC3=O)=O)=O)=O)C=C(COC(N(C)[C@@H](C(C)C)C(N[C@H](C(N(C)[C@@H]([C@H](CC)C)[C@H](OC)CC(N4[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C5=CC=CC=C5)=O)CCC4)=O)=O)C(C)C)=O)=O)C=C2)O[C@@H]1C(O)=O
Biological Activity: MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MC-betaglucuronide-MMAE-1 | 99.23% | MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mc-Phe-Lys-PAB-MMAE | Mc-Phe-Lys-PAB-MMAE (Compound 2) is a drug-linker conjugate for ADC, and can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-Gly-Gly-Phe-Gly-PAB-MMAE | 99.23% | MC-Gly-Gly-Phe-Gly-PAB-MMAE (Compound SMP-81641) is a control targeted linker-agent conjugate. MC-Gly-Gly-Phe-Gly-PAB-MMAE can be used in tumor research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-betaglucuronide-MMAE-2 | 95.00% | MC-betaglucuronide-MMAE-2 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE | 99.82% | Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE (compound S6) is a potent anticancer agent, which can be specific activated by tumor microenvironment. Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE can suppress tumor growth in mice (extracted from patent CN104147612A). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-VA-PABC-MMAE | 99.93% | MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE | Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE (HY-15162) and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid (HY-171663) . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MMAE-PAB(p-glucuronide)-PEG3-aminooxy | MMAE-PAB(p-glucuronide)-PEG3-aminooxy is a compound with potential drug delivery. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VcMMAE (GMP) | VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mc-Pro-PAB-MMAE | 99.16% | Mc-Pro-PAB-MMAE is a Drug-Linker Conjugate for ADC. Mc-Pro-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker. Mc-Pro-PAB-MMAE can be used for synthesis of ADCs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Val-Lys-PAB-MMAE | Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
